Maravai Lifesciences Holdings Inc (MRVI) financials
Maravai Lifesciences revenue and earnings by year
Maravai Lifesciences's revenue was $186 million in the fiscal year to December 31, 2025, down 28.3% from the year before. Net income was -$131 million, -70.4% of revenue. Since the fiscal year to December 31, 2018, revenue has grown 6.0% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 8 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 186 | 259 | 289 | 883 | 799 | 284 | 143 | 124 |
| Revenue growth | -28.3% | -10.3% | -67.3% | 10.5% | 181.3% | 98.5% | 15.6% | — |
| Gross profit | 34 | 108 | 140 | 714 | 659 | 204 | 76 | 63 |
| Gross margin | 18.3% | 41.8% | 48.5% | 80.9% | 82.4% | 72.0% | 53.3% | 50.9% |
| Operating income | -215 | -238 | -35 | 566 | 555 | 120 | 24 | 17 |
| Operating margin | -115.8% | -91.7% | -12.1% | 64.1% | 69.4% | 42.2% | 17.0% | 14.0% |
| Net income | -131 | -145 | -119 | 220 | 182 | 89 | -4 | -4 |
| Net margin | -70.4% | -55.9% | -41.2% | 24.9% | 22.8% | 31.3% | -3.1% | -3.6% |
| Diluted EPS | -$0.90 | -$1.05 | -$0.90 | — | — | — | — | — |
| Free cash flow | -70 | -15 | 74 | 507 | 354 | 143 | 7 | -4 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open MRVI in Markets.
How Maravai Lifesciences makes money
Revenue by segment in the quarter to March 31, 2026, as the company reports it.
| Segment | Revenue | Share |
|---|---|---|
| Nucleic Acid Production | $47.5M | 72.1% |
| Biologics Safety Testing | $18.4M | 27.9% |
See also: MRVI returns
No forecast, no recommendation. This page describes Maravai Lifesciences Holdings Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.